Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys $4,339,267.80 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $7.91 per share, with a total value of $4,339,267.80. Following the completion of the purchase, the director owned 16,231,717 shares in the company, valued at approximately $128,392,881.47. This trade represents a 3.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $8.54 on Friday. The company’s 50 day simple moving average is $8.93 and its 200 day simple moving average is $6.14. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The company has a market capitalization of $211.11 million, a P/E ratio of -2.41 and a beta of 2.38.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wedbush boosted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ARTV. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $79,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $58,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $67,000. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $53,000. Finally, BNP Paribas Financial Markets increased its stake in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.